Search results for "Secondary prophylaxis"

showing 4 items of 4 documents

Secondary prophylaxis vs. on-demand treatment to improve quality of life in severe adult haemophilia A patients: a prospective study in a single cent…

2013

Background Retrospective publications show a decrease in the bleeding frequency and an improvement in the quality of life (QoL) in severe adult haemophilia A (SAHA) after switching from the on-demand treatment (DT) to secondary prophylaxis (SP). But there are no prospective studies which demonstrate, using a haemophilia-specific questionnaire, an improvement in the QoL after such treatment change. The main objective of this study is to prospectively compare the QoL and the musculoskeletal assessment after switching from DT to SP in SAHA using the A36 Hemofilia-QoL®. As secondary objective, we compare the haemarthrosis frequency and factor VIII consumption in DT and SP during a similar perio…

AdultMalePediatricsmedicine.medical_specialtyHaemophilia Ahaemophilia AHemorrhageHemophilia AQuality of lifeSurveys and QuestionnairesHemarthrosismedicineHumansProspective StudiesProspective cohort studyRetrospective StudiesmusculoskeletalFactor VIIIbusiness.industrySecondary prophylaxisHematologyGeneral MedicineMiddle Agedmedicine.diseasehumanitiesbleeding incidenceSingle centreOn demand treatmentquality of lifesecondary prophylaxisQuality of LifeFemalebusinessVox sanguinis
researchProduct

Results of an orthopaedic survey in young patients with severe haemophilia in Spain

2002

Summary.  This paper outlines the results obtained in a cross-sectional study of a group of young patients with severe haemophilia A and B. The primary aim of the study was to ascertain the level of orthopaedic complications in the group, the effects that these complications have on quality of life, and the medical resources used on these patients. The secondary aim was to relate their current orthopaedic state to the type of treatment received before the study. The study was carried out in 11 hospitals in Spain, where 70 severe haemophilia patients (factor VIII [FVIII] < 2%), with an average age of 21.6 and a median age of 22, and no inhibitors, were monitored. The percentage of patients s…

AdultPediatricsmedicine.medical_specialtyAdolescentHaemophilia AHemophilia AHaemophiliaHemophilia BCost of IllnessQuality of lifeOn demandAbsenteeismHemarthrosismedicineHumansYoung adultGenetics (clinical)Retrospective StudiesHaemophilic arthropathybusiness.industrySecondary prophylaxisHematologyGeneral Medicinemedicine.diseaseArthralgiaCross-Sectional StudiesSpainQuality of LifeSevere haemophilia AbusinessHaemophilia
researchProduct

Cardiovascular events and intensity of treatment in polycythemia vera.

2013

A b s t r ac t Background Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. Methods We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit, <45%) (low-hematocrit group) or less intensive treatment (target hematocrit, 45 to 50%) (high-hematocrit group). The primary composite end point was the time until death from cardiovascular causes or major thrombotic events. The secondary end points were cardiovascula…

MaleHematocritRECURRENT THROMBOSISlaw.inventionAged; Antineoplastic Agents; Cardiovascular Diseases; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Thrombosis; Hematocrit; Phlebotomy; Medicine (all)LEUKOCYTOSISPolycythemia veraRandomized controlled trialPhlebotomylawhemic and lymphatic diseasesESSENTIAL THROMBOCYTHEMIAClinical endpointHydroxyureaPolycythemia Vera Secondary ProphylaxisESSENTIAL THROMBOCYTHEMIA RECURRENT THROMBOSIS RISK-FACTOR HEMATOCRIT MANAGEMENT LEUKOCYTOSIS PREVENTION DIAGNOSIS EFFICACY WARFARINPolycythemia Veramedicine.diagnostic_testMedicine (all)Hazard ratioGeneral MedicineMiddle AgedCombined Modality TherapyHematocritCardiovascular DiseasesFemalemedicine.medical_specialtyrandomized trial; polycythemia veraAntineoplastic AgentsCardiovascular eventDIAGNOSISWARFARINRISK-FACTORInternal medicineMANAGEMENTmedicineHumansMyelofibrosisAdverse effectAgedbusiness.industryThrombosisPhlebotomyJanus Kinase 2EFFICACYmedicine.diseasePREVENTIONSurgeryPolycythemia Vera Cardiovascular event hematocritSettore MED/15 - MALATTIE DEL SANGUEbusinessFollow-Up Studies
researchProduct

The orthopaedic status of severe haemophiliacs in Spain

2000

Summary. This paper provides an outline of the results obtained in a cross-sectional study conducted primarily with the aim of ascertaining orthopaedic complications in a group of young severe A and B haemophiliacs, the effects which these complications have on the medical resources used with these patients, and the impact of severe haemophilia on their quality of life. Its secondary aim was to link their current orthopaedic status to the type of treatment they had received prior to the study. Eleven Spanish hospitals took part in this study, monitoring 70 severe haemophiliacs (FVIII:C 6 months). In 40 cases (57.1%) the patients underwent one or more periods of prophylaxis. Thirty-three pat…

medicine.medical_specialtyBleeding episodesHaemophilic arthropathyPediatricsbusiness.industrySecondary prophylaxisHematologyGeneral MedicineHaemophiliamedicine.diseasemedicine.anatomical_structureQuality of lifeRadiological weaponOrthopedic surgerymedicineAnklebusinessGenetics (clinical)Haemophilia
researchProduct